SCHEDULE 13G/A: Blue Owl Capital Holdings LP Discloses Amended 9.99% Stake in Marker Therapeutics, Inc.
Beneficial Ownership Disclosure
Blue Owl Capital Holdings LP has filed an amended Schedule 13G, reporting a 9.99% beneficial ownership stake in Marker Therapeutics, Inc., comprising common stock and exercisable warrants.
Summary
- Blue Owl Capital Holdings LP (the "Reporting Person") has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Marker Therapeutics, Inc.
- The Reporting Person beneficially owns an aggregate of 1,127,052 shares of Marker Therapeutics, Inc. common stock.
- This ownership represents 9.99% of the outstanding common stock of Marker Therapeutics, Inc.
- The beneficial ownership consists of 554,250 shares of common stock directly held and 572,802 shares of common stock issuable upon exercise of warrants.
- The percentage of class is calculated based upon 10,709,005 shares of common stock outstanding as of March 18, 2025, as reported in the Issuer's 10-K, plus the 572,802 shares issuable from warrants.
- The Reporting Person holds a total of 2,570,750 warrants, but a conversion limitation prevents their beneficial ownership from exceeding 9.99%.
- Stockholders of Marker Therapeutics, Inc. approved the issuance of shares of common stock upon exercise of warrants held by the Reporting Person at a special meeting on March 21, 2025.
Sentiment
Score: 6
Explanation: The filing is a routine beneficial ownership disclosure, indicating a significant passive stake by an institutional investor. The approval of warrant exercise is a neutral to slightly positive event as it clarifies the investor's position and potential for increased liquidity, but the conversion limitation is a minor constraint.
Positives
- A significant institutional investor, Blue Owl Capital Holdings LP, maintains a substantial 9.99% beneficial ownership stake in Marker Therapeutics, Inc., indicating continued interest.
- Stockholders approved the issuance of shares upon exercise of warrants held by the Reporting Person, facilitating the conversion of warrants into common stock and clarifying the capital structure.
Negatives
- The Reporting Person's beneficial ownership is subject to a conversion limitation, preventing it from exceeding 9.99% despite holding a larger number of warrants (2,570,750 total warrants), which means a significant portion of their warrant holdings are not currently reflected in their beneficial ownership percentage.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Shareholder Approval | Stockholders approved the issuance of shares of Common Stock upon exercise of warrants held by Blue Owl Capital Holdings LP. | March 21, 2025 | Facilitates the conversion of existing warrants into common stock, clarifying the capital structure related to this significant investor's holdings. |
Stakeholder Impact
- Shareholders: The disclosure provides transparency regarding a significant institutional investor's stake. The approval of warrant exercise could lead to an increase in shares outstanding as warrants are converted, potentially impacting per-share metrics if not already factored into market expectations.
Key Dates
| Date | Description |
|---|---|
| 03/18/2025 | Date 10,709,005 shares of Common Stock were outstanding as reported in Issuer's 10-K. |
| 03/21/2025 | Date stockholders approved the issuance of shares of Common Stock upon exercise of warrants held by the Reporting Person. |
| 03/31/2025 | Date of Event Which Requires Filing of this Statement; also the date Marker Therapeutics, Inc.'s 10-K was filed with the SEC. |
| 05/15/2025 | Date the Schedule 13G Amendment No. 1 was signed by Blue Owl Capital Holdings LP. |
Keywords
Marker Therapeutics, Blue Owl Capital, Schedule 13G, beneficial ownership, common stock, warrants, SEC filing, institutional investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.